AstraZeneca Announces $2 Billion Expansion in Maryland, Creating Thousands of Jobs

Governor Wes Moore and AstraZeneca have revealed plans for a significant $2 billion investment aimed at expanding the company’s manufacturing capabilities within Maryland. This initiative represents the largest private capital investment in the state over the past decade and is projected to create approximately 2,600 jobs. The expansion includes substantial growth at AstraZeneca’s existing biologics manufacturing facility in Frederick and the construction of a new, advanced clinical manufacturing facility in Gaithersburg.

The investment will see the Frederick facility nearly double its commercial manufacturing capacity, a move that will also facilitate the return of AstraZeneca’s extensive rare disease portfolio to the United States. This expansion is expected to generate 200 highly skilled jobs, in addition to 900 roles dedicated to construction, with the facility anticipated to be operational by 2029. Concurrently, the new clinical manufacturing facility in Gaithersburg, also slated for operation by 2029, will add 100 new positions, retain 400 existing roles, and support an estimated 1,000 construction jobs. These developments are part of AstraZeneca’s broader $50 billion investment announced earlier in the year, which includes other recent U.S. commitments such as a new cell therapy manufacturing facility in Rockville.

AstraZeneca, which already employs over 5,500 individuals across its Maryland facilities, is allocating an estimated $1.81 billion for capital expenditures related to this expansion. The state of Maryland, in collaboration with local jurisdictions, is providing support for the project, contributing approximately 10% of the total project costs through an $116.5 million capital budget commitment spread over eight years. Both the expanded Frederick facility and the new Gaithersburg site are designed to adhere to stringent environmental standards and will incorporate advanced technologies such as artificial intelligence, automation, and data analytics.

This significant investment is anticipated to bolster Maryland’s position as a leader in the life sciences and biopharmaceutical sector, contributing to the strengthening of the domestic medicine supply chain. The creation of these jobs will provide new opportunities for Maryland residents in highly skilled and construction-related fields, fostering economic growth and increasing pathways to employment and wealth within the state. The expanded manufacturing capacity will not only benefit the U.S. market but also contribute to global access to transformative treatments.

Article by Mel Anara, based upon information from the Office of Governor Wes Moore

---